Solvay: Paying a Generic Rival to Promote AndroGel

The Solvay AndroGel antitrust case centered on a patent settlement that promised Actavis an estimated $19 to $30 million annually under an agreement delaying its generic launch. The Federal Trade Commission sued in 2009, alleging that Solvay paid to avoid lower-cost competition. A challenger with Food and Drug Administration approval had agreed to promote the brand it was preparing to compete against.

In its June 17, 2013 decision, the Supreme Court allowed the Federal Trade Commission’s challenge to proceed. The Court required an examination of the payments and their commercial purpose.

For an employee who knew the launch plans, promotion arrangements or payment approvals, the business question was concrete. What was Solvay buying from companies that had challenged its patent? The companies said services. The Commission alleged that the real purchase was time without generic competition.

Why Generic Entry Was Worth Buying

Generic entry threatened the revenue Solvay could earn while AndroGel faced no competing generic. The patent challenge put that protection at risk, and the rules governing the first generic launch made the challenger’s position particularly valuable.

Solvay obtained Food and Drug Administration approval for AndroGel in 2000 and obtained a relevant patent in 2003. That year, Actavis, then known as Watson Pharmaceuticals, sought approval for a generic version. Paddock Laboratories applied separately. Both challenged the patent, asserting that it was invalid and that their products did not infringe it.

Par Pharmaceutical took a different role. It joined Paddock rather than submitting its own application, agreeing to share the patent-litigation costs in exchange for a share of the profits if Paddock obtained approval. Solvay therefore faced both generic applicants and a company financing one applicant’s challenge.

Under the Hatch-Waxman system, a generic manufacturer can rely on the approved brand drug’s safety and effectiveness work while showing that its product has the same active ingredients and is biologically equivalent. That abbreviated approval route makes lower-cost entry possible without repeating the brand’s full development process.

The Food and Drug Administration publishes manufacturers’ patent submissions in the Orange Book without independently reviewing the patents. The challengers take their dispute to court.

A timely patent suit generally holds up FDA approval for 30 months while the patent dispute proceeds. The first qualifying generic applicant also has a valuable incentive to challenge the brand: 180 days of exclusivity against later generic applicants after commercial launch. Those rules put a premium on being first and make the nearest challenger especially important to the brand’s business.

Solvay sued Actavis and Paddock. FDA eventually approved Actavis’s product, but the parties settled in 2006. The barrier to that approved product’s launch then included a promise Actavis had made to Solvay.

Solvay’s AndroGel Payments and the Generic Entry Date

Actavis agreed to a generic entry date of August 31, 2015, with earlier entry permitted if someone else marketed a generic sooner. Actavis also agreed to promote AndroGel to urologists, and the other generic companies made roughly similar promises.

Solvay’s payment commitments had different shapes. The opinion identifies $12 million in total for Paddock and $60 million in total for Par. The estimated annual payments to Actavis were to run for nine years.

The companies described the payments as compensation for services. The Federal Trade Commission alleged that those services had little value and that the real purpose was to compensate the challengers for staying out of the market. Its allegation tied together the abandoned patent challenges, the delayed launches and the sharing of Solvay’s monopoly profits.

That was the Commission’s concern about the overall exchange. The companies could both benefit from the agreement while purchasers kept paying prices that earlier generic competition might have reduced. A settlement that suited the manufacturers could still leave the customer paying for their peace.

What the Service Payments Bought

Actavis had won approval to compete with AndroGel. Under the settlement, it would help sell AndroGel instead. Solvay could continue earning brand revenue while paying a potential rival to support that revenue.

A payment tied to the value of work performed tells one story. A large payment that cannot be explained by the services or the costs saved tells another. For someone who priced the promotion work or approved the spending, the useful comparison is between what Solvay promised to pay and what it expected to receive for that money.

The Supreme Court required courts to examine the payment’s size, the cost of continuing the patent fight, the value of the services and any other convincing explanation. The Federal Trade Commission alleged that the services here were worth little compared with Solvay’s payment commitments.

The need to examine what a fee actually buys also appears in manufacturer service-fee reporting. In that separate drug-pricing setting, a bona fide service fee must reflect fair market value for an itemized service actually performed on the manufacturer’s behalf. Misclassifying a price concession as a service fee can leave the average sales price reported for Medicare too high. In Solvay’s case, the antitrust question concerned whether the payment bought services or protection from competition. In both settings, the label on the payment leaves the important question unanswered.

The Court also explained why the antitrust inquiry need not always become a full retrial of the patent dispute. An otherwise unexplained large payment can show how much the brand was willing to spend to remove the risk of competition. The economic reason for the payment can be revealing even without a final answer about the patent’s strength.

Why the Supreme Court Reopened the Case

The Supreme Court reopened the Federal Trade Commission’s challenge. Lower courts had shielded the deal because its restrictions ended before the patent expired. The Supreme Court required courts to examine the arrangement’s competitive effects and the reasons offered for the payment.

The Court also described a different way the parties could settle: agree to generic entry before the patent expired without paying the challenger to stay out until then. That comparison explains why the payment deserved attention of its own. An agreed launch date and a payment to accept that date are different parts of the bargain.

Across pharmaceutical enforcement cases, the direction of the money helps explain what happened. Here, the challenged transaction moved money from a brand manufacturer to its potential competitors. The Supreme Court’s decision opened that transaction to scrutiny.

A Promise Can Transfer Value Without Cash

A later case involving GlaxoSmithKline and Teva shows why a reverse payment can reach beyond a check. In the 2015 appeals court opinion, purchasers challenged a patent settlement concerning Lamictal, whose active ingredient is lamotrigine.

GlaxoSmithKline agreed not to introduce its own authorized generic during Teva’s initial exclusivity period. An authorized generic is the brand’s own generic version, which can compete during a first applicant’s protected launch period. Giving up that competition could leave more sales and higher prices for the generic challenger.

The purchasers alleged that the promise induced Teva to drop its patent challenge and delay entry into the lamotrigine tablet market. The court allowed the challenge to proceed because the promise could transfer substantial value to Teva and serve the same purpose as a cash payment.

For an insider, the parallel widens the commercial question. Value can move through a payment for promotion, or through a promise to withhold a competing product. The relevant business records explain what the recipient gained and what competition the brand expected to avoid.

The Cost of Delaying Generic Competition

Delaying generic competition leaves consumers and taxpayers paying more for medicine. Public Citizen’s 2018 report gives the scale of that cost through an industry-wide FTC estimate:

The report also describes a decline in potential pay-for-delay deals reported by the Federal Trade Commission: from 40 in fiscal 2012 to 21 in fiscal 2014 and 14 in fiscal 2015. That category counted agreements containing both explicit compensation from a brand to a generic and a restriction on the generic’s ability to compete.

The business incentive remains the point of the comparison. When a brand shares protected revenue with a challenger, both companies may gain from waiting. The people buying the medicine need the competition to arrive.

What an Insider Can Explain About the Deal

The strongest account connects the payment, the promised work and the delayed launch. Someone involved in commercial planning may understand why a proposed launch changed. Someone responsible for promotion may know what work the brand expected, while a finance employee may understand how the payment was valued and approved.

Those perspectives meet at the question the Solvay dispute raised. Was the company buying work it valued, or was the payment a way to share the revenue preserved by delaying a competitor? Our whistleblower experts help pharmaceutical whistleblowers turn what they know about deals like this into their strongest case.

For an insider who knows how service payments affected prices reported to Medicare, our experts can assess the connection to false government-payment claims. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Payment Was For

If you know why a generic launch moved or what a promotion agreement really bought, speak to one of our whistleblower experts about what that payment bought. We help turn your knowledge into your strongest whistleblower case, bring in pharmaceutical whistleblower lawyers with the expertise your facts require, and stay beside you as the case develops.